206 related articles for article (PubMed ID: 34008909)
1. Impact of short-term Dutasteride treatment on prostate-specific membrane antigen expression in a mouse xenograft model.
Kranzbühler B; Sousa R; Prause L; Burger IA; Rupp NJ; Sulser T; Salemi S; Eberli D
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1418. PubMed ID: 34008909
[TBL] [Abstract][Full Text] [Related]
2. Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of
Kranzbühler B; Salemi S; Umbricht CA; Deberle LM; Müller C; Burger IA; Hermanns T; Sulser T; Eberli D
Prostate; 2019 Sep; 79(12):1450-1456. PubMed ID: 31233227
[TBL] [Abstract][Full Text] [Related]
3. Improved Prostate-Specific Membrane Antigen (PSMA) Stimulation Using a Super Additive Effect of Dutasteride and Lovastatin In Vitro.
Kuzmanov A; Salemi S; Schmid FA; Burger IA; Eberli D; Kranzbühler B
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569712
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
Kranzbühler B; Salemi S; Umbricht CA; Müller C; Burger IA; Sulser T; Eberli D
Prostate; 2018 Jul; 78(10):758-765. PubMed ID: 29633296
[TBL] [Abstract][Full Text] [Related]
5. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
Ben Jemaa A; Sallami S; Céraline J; Oueslati R
Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
[TBL] [Abstract][Full Text] [Related]
6. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
[TBL] [Abstract][Full Text] [Related]
7. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
Hillier SM; Kern AM; Maresca KP; Marquis JC; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2011 Jul; 52(7):1087-93. PubMed ID: 21680691
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
Evans MJ; Smith-Jones PM; Wongvipat J; Navarro V; Kim S; Bander NH; Larson SM; Sawyers CL
Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9578-82. PubMed ID: 21606347
[TBL] [Abstract][Full Text] [Related]
9. Antihormone treatment differentially regulates PSA secretion, PSMA expression and
Mathy CS; Mayr T; Kürpig S; Meisenheimer M; Dolscheid-Pommerich RC; Stoffel-Wagner B; Kristiansen G; Essler M; Muders MH; Bundschuh RA
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1733-1743. PubMed ID: 33760944
[TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.
Kuroda K; Liu H
Int J Oncol; 2019 Apr; 54(4):1357-1366. PubMed ID: 30720063
[TBL] [Abstract][Full Text] [Related]
11. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
[TBL] [Abstract][Full Text] [Related]
14. Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells.
Sommer U; Siciliano T; Ebersbach C; Beier AK; Stope MB; Jöhrens K; Baretton GB; Borkowetz A; Thomas C; Erb HHH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162969
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
[TBL] [Abstract][Full Text] [Related]
16. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
17. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF
J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
19. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
[TBL] [Abstract][Full Text] [Related]
20. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]